CD274 and cancer: CD274 in TCGA) was a robust positive prognostic factor in the total study cohort (Agilent: 113 out of 444 cutoffs significant (25.5%); optimal cutoff p < 0.0001, Figure 4D; RNAseq: 117 out of 380 cutoffs significant (30.8%), optimal cutoff: p < 0.0001, not shown) as well as in the subgroup with residual tumor after surgery (Agilent: p = 0.0079, Figure 4E; RNAseq: p = 0.0012, not shown), and furthermore in cancers without residual tumor after surgery (Agilent: p = 0.0015, Figure 4F; trend for RNAseq: p = 0.11, not shown).